Table 2 Patients’ clinical and demographic characteristics and findings on SSC, FAS, and CAT.
Age, years | Sex | Handedness | Tumor location | Histology/grade | SSC | FAS | CAT | Genetic markers |
|---|---|---|---|---|---|---|---|---|
36 | F | R | L frontal | GBM/4 | Positive | Negative | Negative | p53, EGFR, PTEN IHC+ |
32 | M | R | L parietal | Oligo-dendroglioma/3 | Positive | Negative | Negative | 1p19q co-deletion, EGFR IHC+, IDH1 exon 4 mutation |
67 | M | R | L frontal | GBM/4 | Positive | Positive | Positive | EGFR IHC+ |
54 | F | L | L parietal | GBM/4 | Positive | Positive | Negative | EGFR IHC+ |
51 | M | R | L insula | Anaplastic oligo-dendroglioma/3 | Positive | Positive | Positive | 1p/19q co-deletion, IDH1 (R132H) IHC+ |
53 | M | R | L posterior temporal | GBM/4 | Positive | Negative | Negative | p53 IHC+, EGFR IHC+ |
18 | F | R | L frontal | Mixed oligo-astrocytoma/3 | Positive | Negative | Negative | IDH1 (R132H) IHC+, EGFR, PTEN IHC+ |
69 | F | R | L inferior temporal | GBM/4 | Positive | Negative | Negative | EGFR IHC+, MGMT promoter methylation |
50 | M | M | L frontal + temporal | GBM/4 | Positive | Negative | Negative | p53 IHC+ |
37 | M | R | L temporal | Oligo-dendroglioma/3 | Positive | Negative | Negative | IDH1 exon 4 mutation, 1p/19q co-deletion |
65 | F | R | L parietal + angular gyri | GBM/4 | Positive | Negative | Negative | EGFR IHC+, PTEN loss of wild-type expression |
45 | M | R | L insula + frontal operculum | GBM/4 | Positive | Negative | Negative | None |
19 | M | R | L parietotemporal | GBM /4 | Positive | Negative | Negative | TP53 exon 8 mutation, IDH1 exon 4 mutation |
33 | M | R | L frontal, + L insula, + L temporal | Oligo-dendroglioma/3 | Positive | Negative | Negative | 1p/19q co-deletion, IDH1 (R132H) IHC+ |
18 | F | R | R frontal + L frontal | Oligo-dendroglioma/2 | Positive | Negative | Negative | 1p/19q co-deletion, IDH1 (R132H) IHC+ |
39 | M | M | R insula, frontal, + temporal | Oligo-dendroglioma/2 | Positive | Negative | Negative | 1p/19q co-deletion, IDH1 (R132H) IHC+ |
62 | M | M | R frontal + insula | GBM/4 | Positive | Negative | Negative | p53 IHC+ |
52 | M | R | L caudate nucleus, internal capsule, + L temporal | GBM/4 | Positive | Negative | Negative | p53 IHC+ |
43 | M | R | L frontal | Astrocytoma/2 | Positive | Positive | Positive | IDH (R132H) IHC+, p53 IHC+ |
43 | M | L | R parietal | GBM/4 | Positive | Negative | Negative | p53, S-100 IHC+ |
51 | F | R | L frontotemporal | GBM/4 | Positive | Negative | Negative | S100 IHC+ |
51 | F | R | L frontal, insula, +anterior temporal | GBM/4 | Positive | Negative | Negative | TP53 exon 7 mutation |
28 | F | L | L frontal | Astrocytoma/3 | Positive | Positive | Positive | IDH-1 R132H) IHC+, EGFR IHC+ |
50 | M | R | R + L frontal | GBM/4 | Positive | Positive | Positive | p53, PTEN, EGFR IHC+ |
31 | F | R | Superior L temporal | Ganglioglioma/2 | Positive | Negative | Negative | None |
62 | M | L | L temporal | GBM/4 | Positive | Negative | Negative | PTEN, EGFR, P53 IHC+ |
54 | M | R | R frontal + L temporal | GBM/4 | Positive | Negative | Negative | p53 IHC+ |
35 | M | L | R occipito-temporal + bifrontal | Astrocytoma/3 | Positive | Negative | Negative | IDH-1 (R132H) IHC+ |
25 | F | R | R frontal | Oligo-dendroglioma/2 | Positive | Positive | Positive | 1p/19q co-deletion,IDH-1 (R132H) IHC+ |
35 | M | R | L posterior temporal | Oligo-dendroglioma | Positive | Positive | Negative | None |
49 | F | R | L temporal | Oligo-dendroglioma | Positive | Positive | Negative | 1p/19q, IDH-2 p.515 G > A IHC+ |
18 | M | R | L temporal | Astrocytoma | Positive | Negative | Negative | p53 IHC+ |
33 | M | R | R superior, middle, +inferior frontal gyri | Astrocytoma | Positive | Positive | Positive | IDH1 (R132H) IHC+ |
48 | M | R | L frontal | Diffuse glioma | Positive | Positive | Positive | IDH1 (R132H) IHC+, 1p/19q co-deletion |
32 | F | M | L frontal | Astrocytoma | Positive | Negative | Negative | IDH1 (R132H) IHC+ |
